RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.21
+7.60%Oct 28, 2026, 10:00 UTC
Rapport Therapeutics announced pricing of a $150.0 million offering of 2.25% convertible senior notes due 2032.
Source:Oct 28, 2026, 10:00 UTC
Rapport Therapeutics announced pricing of underwritten offerings of approximately $175.0 million of common stock and up to approximately $25.0 million of pre-funded warrants, plus a concurrent private placement of approximately $30.0 million of common stock.
Source:Oct 27, 2026, 20:32 UTC
Rapport Therapeutics announced public offerings of $200 million of common stock and $150 million principal amount of convertible senior notes due 2032, along with a concurrent private placement of common stock to an investor.
Source:Oct 20, 2026, 15:38 UTC
Rapport Therapeutics, Inc. shares rose 3.46% to $29.59.
Source:Oct 20, 2026, 10:19 UTC
Rapport Therapeutics, Inc. shares rose as much as 60% in premarket trading.
Source:Oct 20, 2026, 10:00 UTC
Rapport Therapeutics, Inc. reported positive topline results from its Phase 2 trial of RAP-219 for bipolar mania, meeting the primary and secondary endpoints with placebo-adjusted improvements at Week 3.
Aug 5, 2026, 00:00 UTC
Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.